Literature DB >> 8848886

Transpulmonary disposition of prilocaine, mepivacaine, and bupivacaine in humans in the course of epidural anaesthesia.

D Kietzmann1, H Foth, W P Geng, J Rathgeber, U Gundert-Remy, D Kettler.   

Abstract

The pulmonary first-pass kinetics of the amide-linked local anaesthetics prilocaine, mepivacaine and bupivacaine were studied in 33 patients after a single epidural injection. Drug concentrations were monitored before and after lung passage, i.e. in samples withdrawn simultaneously from mixed venous and arterial blood. In most cases, maximum plasma concentrations were observed 10 min after injection (range 2 to 30 min). Two min after injection the local anaesthetics were distinctly extracted by the lung (prilocaine 40%, mepivacaine 20%, and bupivacaine 12%). Prilocaine was retained by the lung more effectively than bupivacaine and mepivacaine. However, a transpulmonary concentration gradient could be observed only for a short time, i.e. maximum 15 min. Altogether, in the case of accidental fast absorption, e.g. inadvertent intravenous injection, arterial peak concentrations of these drugs will be attenuated by passage of the lung. However, the lung will not substantially lower the risk of toxicity by amide-linked local anaesthetics during normal conditions of regional anaesthesia where slow absorption occurs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8848886     DOI: 10.1111/j.1399-6576.1995.tb04192.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  2 in total

1.  [Methemoglobinemia due to prilocaine after plexus anesthesia. Reduction by prophylactic administration of ascorbic acid?].

Authors:  A Kortgen; U Janneck; A Vetsch; M Bauer
Journal:  Anaesthesist       Date:  2003-11       Impact factor: 1.041

2.  Pharmacokinetic profile of epidurally injected bupivacaine in awake patients.

Authors:  R H Taverne; T I Ionescu; A V Dijk
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.